ReviewJournal of clinical & translational endocrinology2026
Growth hormone-releasing hormone, growth hormone, and neuroendocrine tumors.
Review in Journal of clinical & translational endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors (NETs) are known to produce growth hormone (GH) and growth hormone-releasing hormone (GHRH) leading to acromegaly. Ectopic production of these hormones can lead to ectopic acromegaly which is very rare. Ectopic acromegaly secondary to GHRH has been studied more extensively than GH-related ectopic acromegaly. Given the extreme rarity of these neoplasms, comprehensive guidelines for diagnosis and management of these NETs are currently lacking. This review summarizes the literature on clinical presentation, challenges in diagnosis and management of these NETs. The diagnosis of ectopic acromegaly is often difficult as clinical features do not differ from eutopic acromegaly, and we discuss herein when the clinical suspicion should be held high. GHRH serum concentrations are a useful diagnostic tool when ectopic production is suspected. Once the ectopic source is identified using imaging modalities including advanced molecular imaging, the choice of treatment is surgical resection of the respective NET. Other therapies include use of somatostatin receptor analogues and chemo- or immuno-therapies as an adjunct or in refractory cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.